Strategically located at Zhangjiang Pharma Valleyt, Shanghai, China, Star Biolab is a leading expert CRO evaluating new therapies (small, large molecules to medical devices) in animal models of human diseases, including cardiovascular diseases, kidney diseases, fibrotic disorders, inflammation and immune diseases, neurological disorders, rare and genetic diseases, and tumors. The efficacy of new therapies in these models are to be evaluated using technology platforms such as histopathological assessment, IHC, qRT-PCT, western blotting and ELISA to provide most accurate, relevant and integrate conclusion about new therapies. We incorporate translational philosophy to each step of process from testing new therapies in disease models to evaluating efficacy to provide proof of concept to a particular human disease.